SEC filings reveal how GSK's new CEO Luke Miels lined up the $10.6B Nuvalent buyout to land cancer drug neladalkib ahead of an FDA decision.
Luke Miels, GSK CEO
June 24, 2026 08:26 PM EDT
DealsPharma
Kyle LaHucik
Biotech Correspondent
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
GSK is acquiring Nuvalent for $10.6 billion in cash, gaining three late-stage lung cancer therapies including two drugs already…
Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40%…
Luke Miels llevaba solo seis meses como CEO de GSK cuando anunci� la mayor apuesta de su carrera. El megaacuerdo de esta semana,…
GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma…
